Fida Biosystems has raised $5,000,000 in investment capital from investors. The company specializes in biomolecular analysis, offering a proprietary technology that enables direct, transparent measurements under native, in-solution conditions. This platform delivers absolute measurements of hydrodynamic radius, facilitating precise characterization and quantification of proteins and nanoparticles ranging from 0.5 to 1,000 nm Dh, including antibodies, exosomes, and membrane proteins.
The company's innovative technology provides detailed information on affinity (Kd), kinetics (kon & koff), size, concentration, stoichiometry, conformational changes, oligomeric state, and multiple binding events. Crucially, it operates directly in complex biological samples such as plasma, serum, or cell lysate, eliminating the need for surface immobilization. This approach removes non-specific binding artifacts and challenging assay development, ensuring that true binding events are accurately measured. The platform is fast, sample-efficient, and matrix-tolerant, with in-built quality control and automation.
This funding round marks a significant step for Fida Biosystems, providing substantial capital to accelerate its strategic initiatives. The $5,000,000 investment will be primarily used to expand the company's research and development efforts, enhance its commercialization strategies, and scale operational capabilities to meet growing demand. This capital infusion is expected to strengthen Fida Biosystems' position in the competitive life sciences tools market.
Looking ahead, Fida Biosystems plans to leverage this investment to further establish its technology as a standard for transparent and absolute biomolecular data. The company aims to continue empowering scientists and researchers with the precise insights needed to make confident decisions across various stages of research, development, and manufacturing.
